Literature DB >> 21947093

Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country.

B Carrilero1, L Murcia, L Martínez-Lage, M Segovia.   

Abstract

Chagas disease is a disease endemic in Latin America, caused by the parasite Trypanosoma cruzi. Benznidazole is the most commonly used drug for the etiological treatment of the disease although its effectiveness varies according to the phase of the same and toxic side effects are frequent. This prospective study describes the side effects of benznidazole treatment of a cohort of 373 chronic patients. Of these 40.2% presented adverse reactions. The most frequent side effect were dermatological reactions 32.4% (121 of 373) followed by digestive intolerance 9.1% (34 of 373). Surprisingly, three cases of migratory arthritis were observed. Patients treated with benznidazole must be followed up so that the long term incidence of side effects can be studied.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947093

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  16 in total

Review 1.  Chagas disease and transfusion medicine: a perspective from non-endemic countries.

Authors:  Andrea Angheben; Lucia Boix; Dora Buonfrate; Federico Gobbi; Zeno Bisoffi; Simonetta Pupella; Giorgio Gandini; Giuseppe Aprili
Journal:  Blood Transfus       Date:  2015-10       Impact factor: 3.443

2.  Success of benznidazole chemotherapy in chronic Trypanosoma cruzi-infected patients with a sustained negative PCR result.

Authors:  L Murcia; B Carrilero; F Ferrer; M Roig; F Franco; M Segovia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-04       Impact factor: 3.267

3.  A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole.

Authors:  Gilberto Marcelo Sperandio da Silva; Mauro Felippe Felix Mediano; Pedro Emmanuel Alvarenga Americano do Brasil; Mayara da Costa Chambela; Joyce Almeida da Silva; Andrea Silvestre de Sousa; Sergio Salles Xavier; Andrea Rodrigues da Costa; Roberto Magalhães Saraiva; Alejandro Marcel Hasslocher-Moreno
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

4.  Arthritis and benznidazole: more closely related than we thought.

Authors:  E Aldasoro; M J Pinazo; I Oliveira; J Munoz; E Posada; A Requena-Méndez; N Serret; J Gascon
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

5.  Toxic Profile of Benznidazole in Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product from Two Different Manufacturers.

Authors:  I Molina; F Salvador; A Sánchez-Montalvá; B Treviño; N Serre; A Sao Avilés; B Almirante
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

6.  Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity.

Authors:  Juliana da Silva Pacheco; Débora de Souza Costa; Edézio Ferreira Cunha-Júnior; Valter Viana Andrade-Neto; Alan H Fairlamb; Susan Wyllie; Marília O F Goulart; Danyelle C Santos; Thaissa L Silva; Marina A Alves; Paulo R R Costa; Ayres G Dias; Eduardo Caio Torres-Santos
Journal:  ACS Med Chem Lett       Date:  2021-08-16       Impact factor: 4.632

7.  The use of steroids to prevent cutaneous reactions to benznidazole in patients with Chagas disease.

Authors:  Miguel Górgolas; Ignacio Robles; Alfonso Cabello; Ramón Pérez-Tanoira; Concepción Pérez-Jorge Peremarch; Ricardo Fernández-Roblas; Frances Williams; José Manuel Ramos Rincón
Journal:  Pathog Glob Health       Date:  2013-04       Impact factor: 2.894

8.  Multicenter epidemiological and clinical study on imported Chagas diseases in Alicante, Spain.

Authors:  José M Ramos; Diego Torrús; Concepción Amador; Francisco Jover; Fabiola Pérez-Chacón; Yamileth Ponce; Francisco J Arjona; Elena Caro; Concepción Martínez-Peinado; Ingrid Gallegos; José M Cuadrado; Antonio Tello; Felix Gutiérrez
Journal:  Pathog Glob Health       Date:  2012-10       Impact factor: 2.894

9.  Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis.

Authors:  Clara Crespillo-Andújar; Emmanuele Venanzi-Rullo; Rogelio López-Vélez; Begoña Monge-Maillo; Francesca Norman; Ana López-Polín; José A Pérez-Molina
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.228

Review 10.  Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects.

Authors:  Stephen Patterson; Susan Wyllie
Journal:  Trends Parasitol       Date:  2014-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.